Consensus Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2025-07-11 EDT			5-day change	1st Jan Change
109.64 ^USD	-4.28%		-1.89%	+18.70%

07-11	Wall Street Retreats as Investors Monitor Tariffs Updates, Bank Earnings Loom	MT
07-11	Equity Markets Close Lower as Trade Tensions Escalate	MT

Evolution of the Average Target: Gilead Sciences, Inc.

Evolution of the Target Price: Gilead Sciences, Inc.

Changes in Analyst Recommendations: Gilead Sciences, Inc.

86a33422ac64ebf3de320919d39.ug9ZqUsUjYNJK-BWbR1-ShB8jn4EwZ0XB3Q0__DbqbQ.iGQ87zgm6cIRXIJjJ2QyDVo09DtsieRjWCsDxqa__fPjWx7wc3i0-xpa2A~08c9243633df637b16bf82e1fcd68547

Analysts' recommendations: Gilead Sciences, Inc.

HSBC Adjusts Price Target on Gilead Sciences to $91 From $93, Maintains Hold Rating	07-11	MT
RBC Lifts Price Target on Gilead Sciences to $96 From $95, Keeps Sector Perform Rating	07-07	MT
Wolfe Research Adjusts Price Target on Gilead Sciences to $135 From $115	06-20	MT
Analyst recommendations: Lululemon, Micron, Carnival Corp, UnitedHealth…	06-19
RBC Capital Raises Price Target on Gilead Sciences to $95 From $92, Keeps Sector Perform Rating	06-11	MT
DBS Bank Adjusts Price Target on Gilead Sciences to $140 From $125, Maintains Buy Rating	06-02	MT
Mizuho Adjusts Price Target on Gilead Sciences to $117 From $100, Maintains Outperform Rating	05-05	MT
Wolfe Research Adjusts Gilead Sciences Price Target to $115 From $110	05-02	MT
Analyst recommendations: Meta Platforms, Progressive, Equifax, SBA Communications, Cadence Design Systems...	04-29
HSBC Adjusts Gilead Sciences Price Target to $93 From $82, Maintains Hold Rating	04-28	MT
Oppenheimer Adjusts Price Target on Gilead Sciences to $125 From $132, Maintains Outperform Rating	04-25	MT
Goldman Sachs Adjusts Gilead Sciences Price Target to $100 From $97, Maintains Neutral Rating	04-25	MT
Morgan Stanley Raises Price Target on Gilead Sciences to $135 From $130, Keeps Overweight Rating	04-25	MT
RBC Lifts Price Target on Gilead Sciences to $92 From $89, Keeps Sector Perform Rating	04-25	MT
TD Cowen Adjusts Gilead Sciences Price Target to $110 From $100, Maintains Buy Rating	04-23	MT
BMO Capital Adjusts Gilead Sciences Price Target to $120 From $115	04-17	MT
Leerink Partners Adjusts Price Target on Gilead Sciences to $105 From $104, Keeps Outperform Rating	04-17	MT
Goldman Sachs Adjusts Price Target on Gilead Sciences to $97 From $96, Maintains Neutral Rating	04-15	MT
RBC Trims Price Target on Gilead Sciences to $89 From $90, Keeps Sector Perform Rating	04-03	MT
JPMorgan Adjusts Price Target on Gilead Sciences to $130 From $120, Maintains Overweight Rating	03-27	MT
Morgan Stanley Adjusts Price Target on Gilead Sciences to $130 From $123, Keeps Overweight Rating	03-11	MT
BofA Securities Adjusts Gilead Sciences Price Target to $126 From $116, Maintains Buy Rating	03-05	MT
Wells Fargo Adjusts Price Target on Gilead Sciences to $140 From $120, Keeps Overweight Rating	03-05	MT
Oppenheimer Adjusts Price Target on Gilead Sciences to $132 From $115, Keeps Outperform Rating	03-04	MT
Jefferies & Co. Adjusts Gilead Sciences Price Target to $130 From $115, Maintains Buy Rating	02-28	MT

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Ecart obj. / dr
GILEAD SCIENCES, INC.		+6.61%
ELI LILLY AND COMPANY		+20.08%
JOHNSON & JOHNSON		+7.8%
ABBVIE INC.		+8.66%
NOVO NORDISK A/S		+46.89%
ROCHE HOLDING AG		+17.36%
NOVARTIS AG	-	+0.37%
ASTRAZENECA PLC		+30.73%
MERCK & CO., INC.		+22.11%
AMGEN INC.		+6.19%
Average		+16.68%
Weighted average by Cap.		+17.72%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

109.64USD

Average target price

116.88USD

Spread / Average Target

+6.61%

High Price Target

105.00USD

Spread / Highest target

-4.23%

Low Price Target

63.00USD

Spread / Lowest Target

-42.54%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

HSBC
RBC Capital Markets
Wolfe Research
DBS Bank
Mizuho Securities
Oppenheimer
Goldman Sachs
Morgan Stanley
TD Cowen
BMO Capital
Leerink Partners
JPMorgan Chase
BofA Securities
Wells Fargo Securities
Jefferies & Co.
Bernstein
Cantor Fitzgerald
Deutsche Bank Securities
Redburn Atlantic
Daiwa Securities
Baird
Piper Sandler
UBS
Maxim
Truist Securities
Raymond James
Barclays
Argus
SVB Securities LLC
Cowen
SVB Leerink
Credit Suisse
Redburn
DZ BANK	Elmar Kraus